Article Text


Biologics use in sle in 23 centers – data from the international registry for biologics in SLE
  1. R F van Vollenhoven1,
  2. Søren Jacobsen2,
  3. Daniel Wallace3,
  4. John G Hanly4,
  5. Michelle Petri5,
  6. David A Isenberg6,
  7. Ann E Clarke7,
  8. Christian A Pineau8,
  9. Sasha Bernatsky9,
  10. Julia F Simard10,
  11. Sang-Cheol Bae11,
  12. Manuel Ramos-Casals12,
  13. Cándido Díaz-Lagares12,
  14. Guillermo Ruiz-Irastorza13,
  15. Agustín Martínez-Berriotxoa13,
  16. Francisco J García-Hernández14,
  17. Rocío González-León14,
  18. M Jesús Castillo-Palma15,
  19. Luis Saez16,
  20. José Luis Callejas17,
  21. Javier Rascón18,
  22. Enrique de Ramón19,
  23. M Mar Ayala-Gutiérrez19,
  24. Maite Camps19,
  25. Melinda Mild10,
  26. Murat Inanç20,
  27. Bahar Artim-Esen20,
  28. Rosalind Ramsey-Goldman21,
  29. Christine A Peschken22,
  30. Danilo Squatrito23,
  31. Lorenzo Emmi23,
  32. László Kovács24,
  33. Andrea Doria25,
  34. Zoltan Szekanecz26,
  35. Gianfranco Ferraccioli27,
  36. Elisa Gremese28,
  37. Emilia I Sato29
  1. 1Karolinska University Hospital, Stockholm, Sweden
  2. 2Rigshospitalet, Copenhagen, Denmark
  3. 3Cedars-Sinai/UCLA, Los Angeles, California, USA
  4. 4Dalhousie University and Capital Health, Halifax, Canada
  5. 5Johns Hopkins Hospital, Baltimore, Maryland, USA
  6. 6University College London, London, UK
  7. 7McGill UHC/RI, Montreal, Canada
  8. 8McGill Univ Health Center, Montreal, Canada
  9. 9McGill UHC/RVH, Montreal, Canada
  10. 10Karolinska Institutet, Stockholm, Sweden
  11. 11Hanyang University Hospital for Rheumatic Diseases, Seoul, South Korea
  12. 12Hospital Clínic, Barcelona, Spain
  13. 13Hospital de Cruces, Bizkaia, Spain
  14. 14Hospital Virgen del Rocío, Sevilla, Spain
  15. 15Sevilla, Spain
  16. 16Hospital Miguel Servet, Zaragoza, Spain
  17. 17Hospital San Cecilio, Granada, Spain
  18. 18Hospital Son Dureta, Palma de Mallorca, Spain
  19. 19Hospital Carlos Haya, Málaga, Spain
  20. 20Istanbul University, Istanbul Medical Faculty, Istanbul, Turkey
  21. 21Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA
  22. 22Univ of Manitoba, Winnipeg, Canada
  23. 23Careggi Hospital- Florence, Florence, Italy
  24. 24University of Szeged, Szeged, Hungary
  25. 25University of Padova, Padova, Italy
  26. 26University of Debrecen Medical and Health Sciences Center, Debrecen, Hungary
  27. 27Division of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy
  28. 28Rheumatology Unit, Catholic University, Roma, Italy
  29. 29Escola Paulista de Medicina - Universidade Federal de São Paulo, Sao Paulo, Brazil


Backgroundand objectives There is only one biologic agent approved for use in SLE, but some are used off-label in various settings. To obtain information systematically regarding this, members of the SLICC group initiated the International Registry for Biologics in SLE (IRBIS). The objective of this study was to analyse the use of biologics in SLE, and assess results achieved with the most commonly used off-label biologic, rituximab (RTX).

Materials and methods IRBIS investigators were asked to provide retrospective data on all patients treated with a biologic for SLE at their center. Standardised case report forms were used to collect demographic, disease-specific and treatment data at the time of biologic initiation and at yearly follow-up. Data from the first 23 reporting centers are presented.

Results Three hundred and fifty-nine patients were treated off-label with RTX, and additional groups of patients were exposed to belimumab (n=44), epratuzumab (n=21), abatacept (n=4), etanercept (n=3) and adalimumab (n=1). For the RTX treated group, age (mean±SD) was 41.3±13.3 and 91% were female. The majority (76%) were Caucasian, and smaller proportions were Southeast Asian, Asian/Indian, African-American, Latino, Afro-Caribbean or other (each <10%). Disease duration when RTX was initiated was 9.2±7.8 years. SLEDAI at start was 11.3±7.6, SLICC-damage index 1.4±1.5 and glucocorticoid dosage 17.0±15.2 mg. Most patients (78%) had been treated with one or two different immunosuppressives (ISs) prior to RTX, and the remaining with three to five ISs. Two dosing regimens were used for RTX: 375 mg/m2x4 (52%) and 1000 mgx2 (48%). The major organ manifestations leading to RTX treatment were lupus nephritis (LN, 48%), haematological (21%), musculoskeletal, skin disease, CNS and other (each <10%). At 1-year follow-up both SLEDAI and GC dose had decreased (4.2±3.5 (n=106) and 7.9±7.0mg (n=89), respectively, paired samples, p<0.0001 for both comparisons). Exclusion of patients started on additional ISs (n=24) did not change SLEDAI or GC dose significantly. SLEDAI at baseline was higher in LN than in non-LN patients but similar at follow-up. Overall, the 1000 mgx2 was more often used but both dosing regimens appeared equally effective in LN.

Conclusions RTX was the off-label biologic most commonly used in this multi-center international lupus cohort and was used for LN as well as for other SLE manifestations. At one-year-follow-up both lupus activity and concomitant glucocorticoid dosage had decreased even when no other IS treatments had been introduced. The two RTX dosing regimes appeared equally effective for LN treatment, but firm conclusions cannot be made from these observational data.

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.